Converging lines of evidence indicate that near-infrared light treatment, also known as photobiomodulation (PBM), may exert beneficial effects and protect against cellular toxicity and degeneration in several animal models of human pathologies, including neurodegenerative disorders. In the present study, we report that chronic PMB treatment mitigates dopaminergic loss induced by unilateral overexpression of human α-synuclein (α-syn) in the substantia nigra of an AAV-based rat genetic model of Parkinson's disease (PD). In this model, daily exposure of both sides of the rat's head to 808-nm near-infrared light for 28 consecutive days alleviated α-syn-induced motor impairment, as assessed using the cylinder test. This treatment also significantly reduced dopaminergic neuronal loss in the injected substantia nigra and preserved dopaminergic fibers in the ipsilateral striatum. These beneficial effects were sustained for at least 6 weeks after discontinuing the treatment. Together, our data point to PBM as a possible therapeutic strategy for the treatment of PD and other related synucleinopathies.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4617694 | PMC |
| http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0140880 | PLOS |
Publication Analysis
Top Keywords
Similar Publications
Engineered AAV capsid transport mutants overcome transduction deficiencies in the aged CNS.
Mol Ther Nucleic Acids
December 2024
Parkinson's Disease Research Unit, Department of Translational Neuroscience, Barrow Neurological Institute, Phoenix, AZ 85013, USA.
Adeno-associated virus (AAV)-based gene therapy has enjoyed great successes over the past decade, with Food and Drug Administration-approved therapeutics and a robust clinical pipeline. Nonetheless, barriers to successful translation remain. For example, advanced age is associated with impaired brain transduction, with the diminution of infectivity depending on anatomical region and capsid.
View Article and Find Full Text PDFCircular RNA circZFPM2 regulates cardiomyocyte hypertrophy and survival.
Basic Res Cardiol
August 2024
Institute of Molecular and Translational Therapeutic Strategies, Hannover Medical School, Hannover, Germany.
Article Synopsis
- Hypertrophic cardiomyopathy (HCM) is the most common genetic heart disorder, but existing treatments mainly relieve symptoms rather than address root causes; research on circular RNAs (circRNAs) offers new insights.
- A specific circRNA, circZFPM2, was found to be significantly upregulated in HCM cardiac tissue and plays a crucial role in regulating heart cell functions, as shown through experiments in different cell models.
- Delivering circZFPM2 improved heart cell health by reducing hypertrophy and increasing cell survival, suggesting it could be a potential new target for HCM therapies based on its positive effects on heart function and mitochondrial health.
Mannose-coupled AAV2: A second-generation AAV vector for increased retinal gene therapy efficiency.
Mol Ther Methods Clin Dev
March 2024
Nantes Université, CHU de Nantes, INSERM UMR 1089, TaRGeT-Translational Research in Gene Therapy Laboratory, 44200 Nantes, France.
Inherited retinal diseases are a leading and untreatable cause of blindness and are therefore candidate diseases for gene therapy. Recombinant vectors derived from adeno-associated virus (rAAV) are currently the most promising vehicles for therapeutic gene delivery to the retina. However, there is a need for novel AAV-based vectors with greater efficacy for ophthalmic applications, as underscored by recent reports of dose-related inflammatory responses in clinical trials of rAAV-based ocular gene therapies.
View Article and Find Full Text PDFAbsence of functional deficits in rats following systemic administration of an AAV9 vector despite moderate peripheral nerve and dorsal root ganglia findings: A clinically silent peripheral neuropathy.
Neurotoxicology
March 2024
Drug Safety Research and Development, Pfizer Inc., Cambridge, MA 02139, USA.
Adeno-associated virus (AAV)-based vectors are commonly used for delivering transgenes in gene therapy studies, but they are also known to cause dorsal root ganglia (DRG) and peripheral nerve toxicities in animals. However, the functional implications of these pathologic findings and their time course remain unclear. At 2, 4, 6, and 8 weeks following a single dose of an AAV9 vector carrying human frataxin transgene in rats, non-standard functional assessments, including von Frey filament, electrophysiology, and Rotarod tests, were conducted longitudinally to measure allodynia, nerve conduction velocity, and coordination, respectively.
View Article and Find Full Text PDFProper brain function requires the assembly and function of diverse populations of neurons and glia. Single cell gene expression studies have mostly focused on characterization of neuronal cell diversity; however, recent studies have revealed substantial diversity of glial cells, particularly astrocytes. To better understand glial cell types and their roles in neurobiology, we built a new suite of adeno-associated viral (AAV)-based genetic tools to enable genetic access to astrocytes and oligodendrocytes.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!